Double blinded, randomized, Priorix- and placebo-controlled, trial to evaluate the optimal dose of MV-CHIK vaccine (against Chikungunya virus) in regard to immunogenicity, safety and tolerability in healthy volunteers.
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2017
At a glance
- Drugs Chikungunya virus vaccine (Primary) ; Measles mumps and rubella virus vaccine-(Priorix)
- Indications Chikungunya virus infections
- Focus Pharmacodynamics
- Sponsors Themis Bioscience
- 21 Dec 2016 Status changed from not yet recruiting to recruiting.
- 12 Aug 2016 New trial record